What compounds target MAPK9?

BiohacksAI has identified 43 compounds that interact with MAPK9 (mitogen-activated protein kinase 9). Top compounds include: gefitinib, erlotinib, imatinib, sb 203580, foretinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is MAPK9 (mitogen-activated protein kinase)?

MAPK9 is mitogen-activated protein kinase 9. It is a molecular target for 43 compounds documented in PubMed bioassay data. UniProt ID: P45984. NCBI Gene ID: 5601.

MAPK9

MOLECULAR TARGET

mitogen-activated protein kinase 9

UniProt: P45984 NCBI Gene: 560143 compounds

MAPK9 (mitogen-activated protein kinase 9) is targeted by 43 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAPK9

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	erlotinib	5.55	256
3	imatinib	5.47	236
4	sb 203580	4.92	136
5	foretinib	4.34	76
6	ponatinib	4.26	70
7	palbociclib	4.22	67
8	nilotinib	4.17	64
9	doramapimod	4.06	57
10	quizartinib	3.99	53
11	midostaurin	3.85	46
12	sb 202190	3.64	37
13	canertinib	3.53	33
14	tae 684	3.43	30
15	fedratinib	3.40	29
16	gilteritinib	3.40	29
17	linifanib	3.33	27
18	sp 600125	3.22	24
19	at 9283	3.09	21
20	lestaurtinib	3.04	20
21	sp600125	2.89	17
22	momelotinib	2.89	17
23	r 406	2.83	16
24	k 252a	2.83	16
25	azd 5438	2.71	14
26	kw 2449	2.64	13
27	linsitinib	2.64	13
28	ast 487	2.56	12
29	zotiraciclib	2.56	12
30	su 014813	2.20	8
31	rebastinib	2.20	8
32	encorafenib	2.20	8
33	cyc 116	2.08	7
34	mk 2461	2.08	7
35	fostamatinib	2.08	7
36	cep 32496	1.95	6
37	tanzisertib	1.95	6
38	Afatinib	1.10	2
39	Anisomycin	1.10	2
40	Sorafenib	1.10	2
41	cardamonin	0.69	1
42	Hesperidin	0.69	1
43	pictilisib	0.69	1

About MAPK9 as a Drug Target

MAPK9 (mitogen-activated protein kinase 9) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 43 compounds with documented MAPK9 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAPK9 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.